RESUMEN
Limited therapies are available for severe cerebral palsy children (CP) with complex movement disorders, especially when both dystonia and spasticity are present. In this publication, we present the improvement of a child with severe CP after intracerebroventricular baclofen therapy. The treatment can impact not just the movement disorders but also on the quality of life of the child and caregivers. Global functional improvements can be observed on the 6-month follow-up.
Asunto(s)
Parálisis Cerebral , Trastornos del Movimiento , Relajantes Musculares Centrales , Niño , Humanos , Baclofeno , Parálisis Cerebral/complicaciones , Parálisis Cerebral/tratamiento farmacológico , Calidad de Vida , Bombas de Infusión Implantables , Espasticidad Muscular/tratamiento farmacológicoRESUMEN
We aimed to evaluate the characteristics and colonization by pathogenic microorganisms of the ocular surface in patients in a burn center and to determine their association with sedation, mechanical ventilation, and periocular burn. We prospectively evaluated 40 patients during an 8-mo period. Five evaluations where performed, at baseline and weekly on four more occasions or until hospital discharge or death. On each visit, we assessed periocular burn, lid position, Bell's phenomenon, Schirmer's test, presence of chemosis, conjunctival hyperemia, and exposure keratopathy; conjunctival fornix swabs were taken for microbiology culture. Also, we documented the level of sedation, mechanical ventilation status, and systemic and ocular treatment. Absent Bell's phenomenon and chemosis were significantly different at baseline in patients under mechanical ventilation, sedation, and in those with a periocular burn. The cumulative incidence of exposure keratopathy was 22.5% and the cumulative incidence of ocular surface colonization by pathogenic microorganisms was 32.5%. Both outcomes were associated with mechanical ventilation and periocular burn. The most frequent pathogenic microorganisms on the ocular surface were Candida parapsilosis, Acinetobacter baumanii, and Pseudomonas aeuroginosa. We did not observe any case of a persistent epithelial defect, infectious keratitis, corneal perforation or corneal opacity in this cohort. Results from our study may benefit future patients by allowing better risk stratification and treatment strategies for the ocular surface care in burn units.
Asunto(s)
Quemaduras Oculares/complicaciones , Quemaduras Oculares/microbiología , Adulto , Unidades de Quemados , Quemaduras Oculares/terapia , Femenino , Humanos , Hipnóticos y Sedantes/administración & dosificación , Masculino , México , Relajantes Musculares Centrales/administración & dosificación , Estudios Prospectivos , Respiración Artificial , Factores de RiesgoRESUMEN
There are many medications available to treat spasticity, but the tolerability of medications is the main issue for choosing the best treatment. The objectives of this study were to compare the efficacy and adverse effects of tolperisone compared to baclofen among patients with spasticity associated with spinal cord injury. Patients received baclofen plus physical therapy (BAF+PT, n=135) or tolperisone plus physical therapy (TOL+PT, n=116), or physical therapy alone (PT, n=180). The modified Ashworth scale score, the modified Medical Research Council score, the Barthel Index score, and the Disability Assessment scale score were improved (P<0.05 for all) in all the patients at the end of 6 weeks compared to before interventions. After 6 weeks, the overall coefficient of efficacy of the intervention(s) in the BAF+PT, TOL+PT, and PT groups were 1.15, 0.45, and 0.05, respectively. The patients of the BAF+PT group reported asthenia, drowsiness, and sleepiness and those of the TOL+PT group reported dyspepsia and epigastric pain as adverse effects. When comparing drug interventions to physical therapy alone, both baclofen plus physical therapy and tolperisone plus physical therapy played a significant role in the improvement of daily activities of patients. Nonetheless, baclofen plus physical therapy was tentatively effective. Tolperisone plus physical therapy was slightly effective. In addition, baclofen caused adverse effects related to the sedative manifestation (Level of Evidence: III; Technical Efficacy Stage: 4).
Asunto(s)
Relajantes Musculares Centrales , Traumatismos de la Médula Espinal , Tolperisona , Baclofeno/efectos adversos , China , Humanos , Relajantes Musculares Centrales/efectos adversos , Estudios Retrospectivos , Traumatismos de la Médula Espinal/complicacionesRESUMEN
Spasticity is amotor disorder that leads to a resistance to passive jointmovement. Cerebral palsy is the most important cause of spasticity and can be caused by several factors, including multiple gestations, alcoholism, infections, hemorrhages, drowning, and traumatic brain injuries, among others. There aremany scales that help tomeasure andmonitor the degree of impairment of these patients. The initial treatment should focus on the causal factor, such as tumors, inflammation, degenerative diseases, hydrocephalus, etc. Subsequently, the treatment of spastic musculature includes oral or intrathecal myorelaxants, spinal cord electrostimulation, neurotomies, Lissauer tract lesion, dentatotomy and selective dorsal rhizotomy. The latter is a safetechnique, possibleto beperformed inmost centers with neurosurgical support, and it is effective in the treatment of severe spasticity. In this article, the authors describe the surgical technique and conduct a review the literature.
Asunto(s)
Enfermedad de la Neurona Motora/cirugía , Rizotomía/rehabilitación , Espasticidad Muscular/cirugía , Espasticidad Muscular/etiología , Parálisis Cerebral/complicaciones , Procedimientos Quirúrgicos Mínimamente Invasivos/métodos , Rizotomía/métodos , Laminoplastia/métodos , Relajantes Musculares Centrales/uso terapéuticoRESUMEN
PURPOSE: This study aims to describe a new baclofen pump implantation technique with pre-brainstem catheter placement and to demonstrate the benefits that this procedure has in treating spasticity and dystonia. METHODS: We described a new technique to place a baclofen pump catheter anterior to the brainstem. To illustrate the technique, we presented five patients with both spasticity and dystonia in whom conventional treatment was not effective. They each received a baclofen pump with a pre-brainstem catheter. We evaluated the results using the Ashworth scale for spasticity, the Barry-Albright scale for dystonia, and the PedsQL for quality of life assessment. Each patient was evaluated before a surgery and after 6 months of follow-up. RESULTS: There were statistically significant differences in all the physical examination evaluated areas using the Barry-Albright and modified Ashworth scales between the preoperative and the postoperative period. The same applies to the results of the PedsQL quality of life scale. CONCLUSION: We presented an innovative baclofen pump implantation technique with pre-brainstem catheter placement that could be a therapeutic alternative in patients with dystonia and spastic quadriparesis for whom conventional therapy is not effective.
Asunto(s)
Parálisis Cerebral , Relajantes Musculares Centrales , Baclofeno , Tronco Encefálico , Parálisis Cerebral/complicaciones , Parálisis Cerebral/tratamiento farmacológico , Humanos , Bombas de Infusión Implantables , Espasticidad Muscular/tratamiento farmacológico , Calidad de VidaRESUMEN
There are many medications available to treat spasticity, but the tolerability of medications is the main issue for choosing the best treatment. The objectives of this study were to compare the efficacy and adverse effects of tolperisone compared to baclofen among patients with spasticity associated with spinal cord injury. Patients received baclofen plus physical therapy (BAF+PT, n=135) or tolperisone plus physical therapy (TOL+PT, n=116), or physical therapy alone (PT, n=180). The modified Ashworth scale score, the modified Medical Research Council score, the Barthel Index score, and the Disability Assessment scale score were improved (P<0.05 for all) in all the patients at the end of 6 weeks compared to before interventions. After 6 weeks, the overall coefficient of efficacy of the intervention(s) in the BAF+PT, TOL+PT, and PT groups were 1.15, 0.45, and 0.05, respectively. The patients of the BAF+PT group reported asthenia, drowsiness, and sleepiness and those of the TOL+PT group reported dyspepsia and epigastric pain as adverse effects. When comparing drug interventions to physical therapy alone, both baclofen plus physical therapy and tolperisone plus physical therapy played a significant role in the improvement of daily activities of patients. Nonetheless, baclofen plus physical therapy was tentatively effective. Tolperisone plus physical therapy was slightly effective. In addition, baclofen caused adverse effects related to the sedative manifestation (Level of Evidence: III; Technical Efficacy Stage: 4).
Asunto(s)
Humanos , Traumatismos de la Médula Espinal/complicaciones , Tolperisona , Relajantes Musculares Centrales/efectos adversos , Baclofeno/efectos adversos , China , Estudios RetrospectivosRESUMEN
A dor miofascial orofacial vem sendo tratada com analgésicos, anti-inflamatórios, relaxantes musculares, fisioterapia, laserterapia e placas oclusais. Contudo, muitas vezes, tais condutas falham em amenizar o quadro doloroso, havendo a necessidade de testar outras estratégias de tratamento. Metodologia: Uma opção para avaliação experimental dessas terapias seria o teste de dor induzido pela carragenina, associado ao teste de avaliação do limiar nociceptivo, originalmente desenvolvido para avaliar a ação de drogas nas patas de roedores. Sendo assim, o presente estudo analisou a nocicepção causada pela carragenina em masseteres de ratos, através do teste de Von Frey, correlacionando-a com alterações teciduais produzidas por esta droga. A carragenina foi injetada no músculo masseter de ratos, enquanto o grupo controle recebeu soro fisiológico. O limiar nociceptivo foi mensurado com um analgesímetro digital antes da administração da carragenina e 5 horas, 1, 3 e 7 dias após o seu uso. Decorridos 8 dias da intervenção, os animais foram eutanasiados, sendo seus masseteres encaminhados para processamento histológico e coloração H&E. Resultados: Observou-se uma diminuição do limiar da resposta nociceptiva em todos os períodos no grupo com carragenina, quando comparado com o grupo controle, havendo diferença estatisticamente significante nas 5 horas. A análise histológica do grupo experimental mostrou a presença de espaços perimisial e endomisial alargados e preenchidos por uma matriz com alguns linfócitos, muitos macrófagos e raros mastócitos. Conclusão: Os resultados indicaram que a associação de uma droga inflamatória com o método Von Frey pode ser uma opção para o estudo do efeito de terapias de dor miofascial.
Myofascial orofacial pain has been treated with analgesics, anti-inflammatories, muscle relaxants, physiotherapy, laser therapy and occlusal plaques. However, many times, such behaviors fail to alleviate the painful condition, with the need to test other treatment strategies. Methodology: An option for experimental evaluation of these therapies would be the pain test induced by carrageenan associated with the nociceptive threshold assessment test, originally developed to assess the action of drugs on the rodents' feet. Thus, the present study analyzed the nociception caused by carrageenan in rat masseter using the Von Frey test, correlating it with tissue changes produced by this drug. Carrageenan was injected into the masseter muscle of rats, while the control group received saline. The nociceptive threshold was measured with a digital analgesometer before administration of carrageenan and 5 hours, 1, 3 and 7 days after its use. After 8 days of the intervention, the animals were euthanized, and their masseters were sent for histological processing and H&E staining. Results: There was a decrease in the nociceptive response threshold in all periods in the group treated with carrageenan when compared to the control group, with a statistically significant difference at 5 hours. Histological analysis of the experimental group showed the presence of enlarged perimisial and endomisial spaces, filled by a matrix with some lymphocytes, many macrophages and rare mast cells. Conclusion: Results indicated that the association of an inflammatory drug with the Von Frey method may be an option for studying the effect of therapies on myofascial pain.
Asunto(s)
Animales , Masculino , Ratas , Ratas Endogámicas , Carragenina , Nocicepción , Síndromes del Dolor Miofascial , Modalidades de Fisioterapia , Ferulas Oclusales , Analgésicos , Antiinflamatorios , Relajantes Musculares CentralesRESUMEN
Tizanidine hydrochloride is a centrally acting skeletal muscle relaxant used in the treatment of spasticity. This drug is sold only as tablets or capsules, which highlights the need to develop oral liquid formulations that allow administration to children and adults with impaired swallowing. This study aim was to develop and improve tizanidine hydrochloride liquid formulations from raw material and to evaluate their stability. A stability-indicating high performance liquid chromatography method was validated for two formulations developed. Fifteen formulations were developed containing syrup and fifteen containing sodium carboxymethyl cellulose as vehicles, to select the two most suitable for stability testing. The formulations were prepared in triplicate and placed in amber polyethylene terephthalate and glass bottles, which were stored under three different conditions: at room temperature (15-30°C), under refrigeration (2-8°C), and at 40°C. The physicochemical and microbiological stability of formulations were evaluated, applying high performance liquid chromatography and microbiological count. The studied formulations at 15-30°C, 2-8°C, and 40°C can be used for a period of 70 days, and all parameters are inside of recommended specifications, enough to allow its use in the context for which it was developed, the application in hospital. The formulations developed in this work have simple components to avoid adverse reactions in vulnerable populations. Results of this study could be applied as a reference for hospital use; once it demonstrated the reliability of storage time interval and proper conditions for use.
Asunto(s)
Clonidina/análogos & derivados , Relajantes Musculares Centrales/administración & dosificación , Administración Oral , Niño , Clonidina/administración & dosificación , Clonidina/química , Estabilidad de Medicamentos , Hospitales , Humanos , Relajantes Musculares Centrales/química , Pediatría , Reproducibilidad de los ResultadosRESUMEN
OBJECTIVE: To report on a case of malignant hyperthermia in a child after a magnetic resonance imaging of the skull was performed using sevoflurane anesthesia. CASE DESCRIPTION: A 3-year-old boy admitted to the pediatric intensive care unit after presenting clinical and laboratory findings consistent with unspecified viral meningoencephalitis. While the patient was sedated, a magnetic resonance imaging of the skul was performed using propofol followed by the administration of sevoflurane through a laryngeal mask in order to continue anesthesia. Approximately three hours after the start of the procedure, the patient presented persistent tachycardia, tachypnea, generalized muscular stiffness and hyperthermia. With a diagnostic hypothesis of malignant hyperthermia, dantrolene was then administered, which immediately induced muscle stiffness, tachycardia, tachypnea and reduced body temperature. COMMENTS: Malignant hyperthermia is a rare pharmacogenetic syndrome characterized by a severe hypermetabolic reaction after the administration of halogenated inhalational anesthetics or depolarizing muscle relaxants such as succinylcholine, or both. Although it is a potentially fatal disease, the rapid administration of continued doses dantrolene has drastically reduced the morbidity and mortality of the disease.
Asunto(s)
Anestésicos por Inhalación/efectos adversos , Imagen por Resonancia Magnética , Hipertermia Maligna/etiología , Sevoflurano/efectos adversos , Aciclovir/uso terapéutico , Anestésicos por Inhalación/administración & dosificación , Anestésicos Intravenosos/administración & dosificación , Antivirales/uso terapéutico , Preescolar , Dantroleno/uso terapéutico , Humanos , Masculino , Hipertermia Maligna/tratamiento farmacológico , Meningoencefalitis/tratamiento farmacológico , Meningoencefalitis/virología , Relajantes Musculares Centrales/uso terapéutico , Propofol/administración & dosificación , Sevoflurano/administración & dosificaciónRESUMEN
ABSTRACT Objective: To report on a case of malignant hyperthermia in a child after a magnetic resonance imaging of the skull was performed using sevoflurane anesthesia. Case description: A 3-year-old boy admitted to the pediatric intensive care unit after presenting clinical and laboratory findings consistent with unspecified viral meningoencephalitis. While the patient was sedated, a magnetic resonance imaging of the skul was performed using propofol followed by the administration of sevoflurane through a laryngeal mask in order to continue anesthesia. Approximately three hours after the start of the procedure, the patient presented persistent tachycardia, tachypnea, generalized muscular stiffness and hyperthermia. With a diagnostic hypothesis of malignant hyperthermia, dantrolene was then administered, which immediately induced muscle stiffness, tachycardia, tachypnea and reduced body temperature. Comments: Malignant hyperthermia is a rare pharmacogenetic syndrome characterized by a severe hypermetabolic reaction after the administration of halogenated inhalational anesthetics or depolarizing muscle relaxants such as succinylcholine, or both. Although it is a potentially fatal disease, the rapid administration of continued doses dantrolene has drastically reduced the morbidity and mortality of the disease.
RESUMO Objetivo: Relatar um caso de hipertermia maligna em criança após exame de ressonância magnética de crânio realizada sob efeito anestésico de sevoflurano. Descrição do caso: Menino de três anos de idade, admitido na Unidade de Terapia Intensiva Pediátrica (UTIP) após apresentar quadros clínico e laboratorial compatíveis com meningoencefalite viral não especificada. Foi realizado um exame de ressonância magnética de crânio com sedação utilizando, na indução anestésica, o propofol seguido pela administração de sevoflurano por meio de máscara laríngea para manutenção anestésica. Aproximadamente três horas após o início do procedimento, o paciente apresentou taquicardia, taquipneia, rigidez muscular generalizada e hipertermia persistentes. Com hipótese diagnóstica de hipertermia maligna, foi então administrado dantrolene, que fez ceder de forma imediata a rigidez muscular, a taquicardia, a taquipneia e reduziu a temperatura corporal. Comentários: A hipertermia maligna é uma síndrome farmacogenética rara, que se caracteriza por reação hipermetabólica grave após administração de anestésicos inalatórios halogenados e/ou relaxantes musculares despolarizantes, como a succinilcolina. Apesar de ser uma doença potencialmente fatal, a rápida administração de dantrolene, junto às doses de manutenção, tem reduzido drasticamente a morbimortalidade da doença.
Asunto(s)
Humanos , Masculino , Preescolar , Imagen por Resonancia Magnética , Anestésicos por Inhalación/efectos adversos , Sevoflurano/efectos adversos , Hipertermia Maligna/etiología , Antivirales/uso terapéutico , Aciclovir/uso terapéutico , Propofol/administración & dosificación , Anestésicos Intravenosos/administración & dosificación , Anestésicos por Inhalación/administración & dosificación , Dantroleno/uso terapéutico , Sevoflurano/administración & dosificación , Hipertermia Maligna/tratamiento farmacológico , Meningoencefalitis/tratamiento farmacológico , Meningoencefalitis/virología , Relajantes Musculares Centrales/uso terapéuticoRESUMEN
BACKGROUND AND AIM: Simaba ferruginea A.St.-Hil. Popularly known as "calunga," is a typical Brazilian cerrado plant whose rhizomes are popular for treating diarrhea. AIMS: The aim of this study was to evaluate the spasmolytic activity and the antidiarrheal effect of the ethanolic extract obtained from S. ferruginea (Sf-EtOH). METHODS: Ileal segments (1-2 cm) from male Wistar rats were mounted in isolated organ baths and connected to a force transducer, and then to an amplifier which was connected to a computer (AVS Projetos/São Paulo-SP). After stabilization for 60 min, under tension (1 gf), two submaximal contractions were induced with KCl 40 mM or carbachol 10-6 M on ileal segments. During the third tonic and sustained contraction, Sf-EtOH was added in cumulative concentrations to the organ bath. Incubations with L-NAME (10-4 M), ODQ (10-5 M), TEA+ (5 or 1 mM), glibenclamide (10-5 M), or apamine (100 nM) were prepared (n = 5), separately and used to verify the involvement of the nitric oxide synthase, guanylate cyclase, and potassium channels in the relaxing effect. The results were expressed as mean ± standard error of the mean and were statistically evaluated using one-way ANOVA followed by Bonferroni test, when necessary *p < 0.05. RESULTS: Sf-EtOH promotes relaxation on rat isolated ileum pre-contracted with CCh and KCl in a concentration-dependent manner. Sf-EtOH also inhibited ileum contractions against cumulative concentrations of carbachol (CCh), KCl, and CaCl2, shifting the curves to the right in a non-parallel manner with an Emax reduction. In the presence of potassium channel blockers, Sf-EtOH shifted the curves to the right with a reduction of Emax, suggesting the involvement of BKCa, KATP, and SKCa in its spasmolytic effect. In the presence of L-NAME or ODQ, the relaxation curves were shifted to the right, suggesting the involvement of this pathway in Sf-EtOH spasmolytic effect. CONCLUSIONS: Sf-EtOH acts in a concentration-dependent manner, involving the positive modulation of K+ channels and NO pathway.
Asunto(s)
Guanilato Ciclasa/metabolismo , Íleon/metabolismo , Óxido Nítrico Sintasa/metabolismo , Parasimpatolíticos/farmacología , Canales de Potasio/metabolismo , Simaroubaceae , Animales , Relación Dosis-Respuesta a Droga , Íleon/efectos de los fármacos , Masculino , Relajantes Musculares Centrales/aislamiento & purificación , Relajantes Musculares Centrales/farmacología , Técnicas de Cultivo de Órganos , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/farmacología , Hojas de la Planta , Ratas , Ratas WistarAsunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto , Persona de Mediana Edad , Baclofeno/uso terapéutico , Síndrome de Rumiación/tratamiento farmacológico , Relajantes Musculares Centrales/uso terapéutico , Método Doble Ciego , Reproducibilidad de los Resultados , Resultado del Tratamiento , Estudios Cruzados , Medicina Basada en la Evidencia , Eructación/tratamiento farmacológico , Reflujo Laringofaríngeo/tratamiento farmacológicoRESUMEN
The anesthesiologist is the specialist who most often faces allergic reactions due to the number of drugs and substances that are exposed to the patient during the course of an intervention. Although they are rare, they have a mortality rate between 3% and 10%. We present a clinical case of a 42-year-old woman with a history of anaphylactic reaction grade 2 that is coordinated for a Werthein-Meigs surgery, for which it is decided to test her with skin tests. The results were positive for morphine, fentanil, remifentanil and atracurium, which directly affected the perioperative management.
El anestesiólogo es el especialista que con mayor frecuencia se enfrenta a reacciones alérgicas por el número de fármacos y sustancias a las que se expone al paciente en el transcurso de una intervención. Si bien son poco frecuentes presentan una mortalidad entre 3 a 10%. Presentamos un caso clínico de una mujer de 42 años con un antecedente de reaccion anafiláctica grado 2 que se coordina para una cirugía de Werthein- Meigs, por lo cual se decide testearla con pruebas cutáneas. Los rsultados fueron positivos para morfina, fentani, remifentanil y atracurio, lo cual incidió directamente en el manejo perioperatorio.
Asunto(s)
Humanos , Femenino , Adulto , Cuidados Preoperatorios , Anafilaxia/diagnóstico , Anafilaxia/prevención & control , Anestesia de Conducción/métodos , Pruebas Cutáneas , Alcaloides Opiáceos/efectos adversos , Anafilaxia/inducido químicamente , Anestésicos Locales , Relajantes Musculares Centrales/efectos adversosRESUMEN
TECNOLOGIA: Tizanidina (Sirdalud®). INDICAÇÃO NA BULA: Espasmo muscular doloroso associado à distúrbios estáticos e funcionais da coluna (síndromes cervical e lombar) e após cirurgia, como por exemplo, de hérnia de disco intervertebral ou de osteoartrite do quadril. Também é indicado para a espasticidade decorrente de distúrbios neurológicos, tais como: esclerose múltipla, mielopatia crônica, doenças degenerativas da medula espinhal, acidentes cerebrovasculares e paralisia cerebral. PERGUNTA: Tizanidina é eficaz e segura para o tratamento do espasmo muscular doloroso? EVIDÊNCIAS: Foram incluídas duas revisões sistemáticas e um ensaio clínico randomizado. Uma revisão sistemática sugere que baclofeno e tizanidina têm eficácia semelhante em pacientes com espasticidade e que tizanidina está associada a maior frequencia de boca seca, enquanto baclofeno com maior fraqueza. Além disso, tizanidina foi eficaz em comparação com o placebo em pacientes com espasticidade (principalmente associada a esclerose múltipla, dor nas costas ou dor no pescoço). Outra revisão sistemática indicou que tizanidina não apresenta diferença na eficácia para baclofeno e diazepam. Em comparação com placebo, tizanidina reduziu o tônus muscular em até 34%. Os eventos adversos associados à tizanidina (que ocorreram em 60 a 88% dos pacientes) foram principalmente sonolência e boca seca, e com menor frequência, alteração nas enzimas hepáticas. O ensaio clínico randomizado demonstrou que tizanidina é eficaz contra placebo e possui eficácia comparável a tiocolchicósido no tratamento da dor lombar aguda associada a espasmos musculares. CONCLUSÕES: Com base em evidências derivadas de estudos de baixa qualidade, tizanidina demonstrou ser eficaz em comparação com o placebo e não apresenta diferença em termos de eficácia para outros comparadores ativos, como baclofeno e diazepam. O principal evento adverso associado ao medicamento foi boca seca. O medicamento não apresenta registro na EMA. Estudos mais robustos são necessários para confirmar a eficácia da tizanidina dentro da sua indicação clínica.(AU)
Asunto(s)
Humanos , Agonistas alfa-Adrenérgicos/uso terapéutico , Relajantes Musculares Centrales/uso terapéutico , Espasticidad Muscular/tratamiento farmacológico , Espasmo/tratamiento farmacológico , Brasil , Análisis Costo-Beneficio , Evaluación de la Tecnología BiomédicaRESUMEN
Objetivo: Analisar na perspectiva do idoso as evidências científicas relativas ao emprego terapêutico e a segurança de relaxantes musculares registrados no Brasil. Método: estudo de análise da oferta de medicamentos contendo fármacos do grupo M03B - Relaxantes musculares de ação central da classificação Anatômica Terapêutica Química. Verificaram-se os fármacos do grupo M03B registrados no Brasil. Pesquisaram-se as evidências científicas relativas à segurança e eficácia. Analisou-se a disponibilidade de informações sobre segurança na bula. Resultados: Identificou-se 18 fármacos do grupo M03B, dos quais 7 (38,9%) estão registrados no Brasil. Das 67 especialidades registradas, 35 (52,2%) são associações farmacológicas. Conclusão: As evidências para uso de relaxantes musculares em idosos são limitadas. As bulas desses medicamentos não apresentam informações relevantes sobre eventos adversos (AU).
OBJECTIVE: To analyze the scientific evidence regarding the therapeutic use and safety of muscle relaxant medicines registered in Brazil from the perspective of the health of the elderly. METHODS: This is a study of the analysis of the supply of medicines containing group M03B drugs Centrally acting muscle relaxants of the Anatomical Therapeutic Chemical classification. The M03B group drugs registered in Brazil were observed. The scientific evidence on safety and efficacy has been investigated. The availability of safety information in the package leaflet was analyzed. RESULTS: We identified 18 drugs from group M03B, of which 7 (38.9%) are registered in Brazil. Of the 67 specialties registered, 35 (52.2%) are pharmacological associations. CONCLUSION: Evidence for the use of muscle relaxants in the elderly is limited. The package leaflets do not contain relevant information on adverse events (AU).
Asunto(s)
Vigilancia de Productos Comercializados , Salud del Anciano , Prospectos de Medicamentos , Relajantes Musculares CentralesRESUMEN
Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal complication of the use of certain medications. It is being seen more often in the pediatric population because of the increasing use of both typical and atypical antipsychotics in children. Rapid recognition of NMS is important to emergency physicians because timely treatment can be life saving. Acute dystonia is also a well-known and more common adverse effect of certain types of antipsychotics, more commonly seen with the typical antipsychotics versus the atypical antipsychotics. We describe a case of a pediatric patient who developed an acute dystonic reaction versus NMS soon after starting aripiprazole. We compare this case with the other documented cases of acute dystonia and NMS after initiating aripiprazole in the pediatric population.
Asunto(s)
Antipsicóticos/efectos adversos , Aripiprazol/efectos adversos , Distonía/inducido químicamente , Niño , Dantroleno/uso terapéutico , Distonía/tratamiento farmacológico , Servicio de Urgencia en Hospital , Humanos , Masculino , Relajantes Musculares Centrales/uso terapéutico , Síndrome Neuroléptico Maligno/diagnósticoRESUMEN
Dystrophin, an important protein of the dystrophin-glycoprotein complex, has been implicated in the pathogenesis of experimental Chagas disease. It is important for the maintenance of cell shape and contraction force transmission. Dystrophin loss has been related to end-stage cardiac myopathies and proposed as a common route for myocardial dysfunction and progression to advanced heart failure. Evidence suggests that calpains, calcium-dependent proteases, digest dystrophin when the calcium concentration is compatible with their activation. The objective of this in vitro study was to test the hypothesis that dantrolene, a calcium channel blocker, improves structural changes induced by serum from Trypanosoma cruzi-infected mice. Cultured neonatal cardiac myocytes were incubated with serum from T. cruzi-infected mice and treated with dantrolene for 24 h. Immunofluorescence and immunoblotting were performed to evaluate dystrophin and calpain-1 protein expression. The levels of dystrophin decreased 13 % and calpain increased 17 % after incubation of cultured neonatal cardiac myocytes with serum from T. cruzi-infected mice. The treatment with dantrolene restored the dystrophin and calpain levels near control levels. Our results demonstrate that alterations in calcium homeostasis in cardiac myocytes are responsible, in part, for cardiac structural changes in experimentally induced T. cruzi myocarditis and that calpain inhibitors may be beneficial in Chagasic heart disease.
Asunto(s)
Enfermedad de Chagas/sangre , Dantroleno/farmacología , Distrofina/química , Suero , Trypanosoma cruzi , Animales , Animales Recién Nacidos , Células Cultivadas , Enfermedad de Chagas/patología , Técnica del Anticuerpo Fluorescente , Ratones , Relajantes Musculares Centrales/farmacología , Miocitos CardíacosRESUMEN
PURPOSE: An initiative to optimize the treatment of malignant hyperthermia in surgical patients through a dantrolene product conversion program is described. SUMMARY: A large health system's formulary evaluation of a new dantrolene sodium product indicated that despite a higher cost per treatment course, the product could offer key advantages over older formulations of dantrolene in terms of preparation and administration time, product content, and storage requirements. A work group, consisting of pharmacy personnel, an anesthesiologist, a nurse anesthetist, and a representative of the health system's group purchasing organization, determined that a switch to the new dantrolene product would offer both patient care benefits and process benefits. With the approval of the health system's pharmacy and therapeutics committee, the new product was added to the formulary as the preferred dosage form of dantrolene, and existing dantrolene product stock was converted to the new formulation. Key implementation steps included (1) concurrent replacement of dantrolene stock on all "malignant hyperthermia carts" across the 15-hospital health system, (2) development of educational materials to raise awareness of the conversion and revised product preparation procedures, (3) anesthesiology provider and pharmacy staff education, (4) revision of dantrolene listings in each hospital's computerized prescriber-order-entry system, and (5) redistribution of returned dantrolene product stock. The dantrolene product conversion occurred over a four-month period. CONCLUSION: A multifacility health system was successful in converting an existing stock of dantrolene to a newly available formulation.
Asunto(s)
Planificación en Salud Comunitaria/métodos , Dantroleno/administración & dosificación , Composición de Medicamentos/métodos , Hipertermia Maligna/tratamiento farmacológico , Relajantes Musculares Centrales/administración & dosificación , Servicio de Farmacia en Hospital/métodos , Planificación en Salud Comunitaria/tendencias , Composición de Medicamentos/tendencias , Humanos , Hipertermia Maligna/diagnóstico , Servicio de Farmacia en Hospital/tendenciasRESUMEN
The essential oil of Alpinia zerumbet (EOAz) presents myorelaxant and antispasmodic actions on cardiac and smooth muscles. The aim of this study was to investigate the effect of EOAz on the skeletal muscle contraction in post-stroke spasticity. Fifteen adults with unilateral hemiparesis and spasticity resulting from stroke were submitted to surface electromyography readings of the gastrocnemius muscle, before and after 10 daily applications (dermal 0.05 mL per muscle belly) of EOAz. The healthy contralateral muscles without applying the oil were used as controls. The analysis showed that, in both lateral and medial gastrocnemius, the values of all studied variables (root mean square, maximum amplitude and median power frequency) were significantly decreased in pathological legs during muscle contraction (Wilcoxon test, p < 0.05). Moreover, spastic muscles presented different results before and after dermal application of EOAz: The mean values of root mean square and median power frequency were significantly increased in lateral and medial gastrocnemius, and also, the maximum amplitude increased in medial gastrocnemius (Mann-Whitney test, p < 0.05). The results suggest that EOAz acts in the skeletal spastic muscle contraction by promoting relaxation and improvement of the muscular performance. Thus, the EOAz can be useful for the clinical management of secondary effects in patients with cerebral vascular disease.
Asunto(s)
Alpinia/química , Relajantes Musculares Centrales/uso terapéutico , Músculo Esquelético/efectos de los fármacos , Aceites Volátiles/uso terapéutico , Espasmo/prevención & control , Accidente Cerebrovascular/complicaciones , Administración Cutánea , Adulto , Electromiografía , Femenino , Cromatografía de Gases y Espectrometría de Masas , Humanos , Masculino , Relajantes Musculares Centrales/administración & dosificación , Relajantes Musculares Centrales/aislamiento & purificación , Aceites Volátiles/administración & dosificación , Aceites Volátiles/aislamiento & purificación , Hojas de la Planta/química , Espasmo/etiologíaRESUMEN
OBJECTIVE: To analyze the incidence and factors associated with constipation in critically ill children. STUDY DESIGN: We performed a prospective observational study that included children admitted to the pediatric intensive care unit for more than 3 days. Constipation was defined as more than 3 days without a bowel movement. Relationships between constipation and demographic data; clinical severity score; use of mechanical ventilation, use of vasoconstrictors, sedatives, and muscle relaxants; nutritional data; electrolyte disturbances; and clinical course were analyzed. RESULTS: Constipation developed in 46.7% of the 150 patients studied (mean age, 34.3 ± 7.1 months). It was most common in postoperative, older, and higher-body-weight patients, and in those with fecal continence (P < .01). Compared with patients without constipation, patients with constipation had higher severity scores and more frequently received midazolam, fentanyl, muscle relaxants, and inotropic support (P < .05). Patients with constipation also started nutrition later and with a lower volume of nutrition (P < .01). There were no between-group differences in mortality or length of pediatric intensive care unit stay. In multivariate analysis, independent factors associated with constipation were body weight (OR, 1.08; 95% CI, 1.03-1.13), Pediatric Index of Mortality 2 score (OR, 1.05; 95% CI, 1.02-1.09), admission after surgery (OR, 7.64; 95% CI, 2.56-22.81), and treatment with vasoconstrictors (OR, 10.28; 95% CI, 3.53-29.93). CONCLUSION: Constipation is common in critically ill children. Body weight, Pediatric Index of Mortality 2 clinical severity score, admission after surgery, and the need for vasoconstrictor therapy are major independent risk factors associated with constipation.